Quercetin decreases the activity of matrix metalloproteinase-2 and ameliorates vascular remodeling in renovascular hypertension

Atherosclerosis

Volumn 270, Issue , 2018, Pages 146-153

  Pereira, Sherliane C ^a   Parente, Juliana M ^a   Belo, Vanessa A ^a   Mendes, Atlante S ^a   Gonzaga, Natália A ^a   do Vale, Gabriel T ^a   Ceron, Carla S ^a,b   Tanus Santos, José Eduardo ^a   Tirapelli, Carlos R ^a   Castro, Michele M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

Author keywords

Antioxidant; Hypertension; Matrix metalloproteinase; Oxidative stress; Vascular remodeling

Indexed keywords

FOCAL ADHESION KINASE; GELATINASE; GELATINASE A; HYDROETHIDINE; QUERCETIN; REACTIVE OXYGEN METABOLITE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ANTIOXIDANT; FOCAL ADHESION KINASE 1; MMP2 PROTEIN, RAT; PTK2 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NONHUMAN; OXIDATIVE STRESS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; AORTA; DISEASE MODELS, ANIMAL; FOCAL ADHESION KINASE 1; HYPERTENSION, RENOVASCULAR; MALE; MATRIX METALLOPROTEINASE 2; OXIDATIVE STRESS; PHOSPHORYLATION; QUERCETIN; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; VASCULAR REMODELING;

EID: 85041401361     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2018.01.031     Document Type: Article

References (45)

1. Touyz, R.M., Briones, A.M., Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens. Res. 34 (2011), 5–14.
2. Griendling, K.K., FitzGerald, G.A., Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 108 (2003), 2034–2040.
3. Konior, A., Schramm, A., Czesnikiewicz-Guzik, M., et al. NADPH oxidases in vascular pathology. Antioxidants Redox Signal. 20 (2014), 2794–2814.
4. Kyaw, M., Yoshizumi, M., Tsuchiya, K., et al. Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol. Sin. 25 (2004), 977–985.
5. Yoshizumi, M., Tsuchiya, K., Suzaki, Y., et al. Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway. Biochem. Biophys. Res. Commun. 293 (2002), 1458–1465.
6. Yan, L., Zhang, J.D., Wang, B., et al. Quercetin inhibits left ventricular hypertrophy in spontaneously hypertensive rats and inhibits angiotensin II-induced H9C2 cells hypertrophy by enhancing PPAR-gamma expression and suppressing AP-1 activity. PLoS One, 8, 2013, e72548.
7. Moon, S.K., Cho, G.O., Jung, S.Y., et al. Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9. Biochem. Biophys. Res. Commun. 301 (2003), 1069–1078.
8. Kleemann, R., Verschuren, L., Morrison, M., et al. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 218 (2011), 44–52.
9. Ali, M.H., Mungai, P.T., Schumacker, P.T., Stretch-induced phosphorylation of focal adhesion kinase in endothelial cells: role of mitochondrial oxidants. Am. J. Physiol. Lung Cell Mol. Physiol. 291 (2006), L38–L45.
10. Moraes, J.A., Frony, A.C., Dias, A.M., et al. Alpha1beta1 and integrin-linked kinase interact and modulate angiotensin II effects in vascular smooth muscle cells. Atherosclerosis 243 (2015), 477–485.
11. Rodrigues, G.J., Lunardi, C.N., Lima, R.G., et al. Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats. Nitric Oxide 18 (2008), 176–183.
12. Castro, M.M., Rizzi, E., Rodrigues, G.J., et al. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic. Biol. Med. 46 (2009), 1298–1307.
13. Escobales, N., Crespo, M.J., Oxidative-nitrosative stress in hypertension. Curr. Vasc. Pharmacol. 3 (2005), 231–246.
14. Grote, K., Flach, I., Luchtefeld, M., et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ. Res. 92 (2003), e80–86.
15. Rajagopalan, S., Meng, X.P., Ramasamy, S., et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98 (1996), 2572–2579.
16. Viappiani, S., Nicolescu, A.C., Holt, A., et al. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem. Pharmacol. 77 (2009), 826–834.
17. Belo, V.A., Guimaraes, D.A., Castro, M.M., Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension. J. Vasc. Res. 52 (2015), 221–231.
18. Castro, M.M., Rizzi, E., Figueiredo-Lopes, L., et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198 (2008), 320–331.
19. Castro, M.M., Rizzi, E., Prado, C.M., et al. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol. 29 (2010), 194–201.
20. Bouvet, C., Gilbert, L.A., Girardot, D., et al. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45 (2005), 432–437.
21. Martinez-Lemus, L.A., Zhao, G., Galinanes, E.L., et al. Inward remodeling of resistance arteries requires reactive oxygen species-dependent activation of matrix metalloproteinases. Am. J. Physiol. Heart Circ. Physiol. 300 (2011), H2005–H2015.
22. Martinez-Lemus, L.A., Hill, M.A., Meininger, G.A., The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology 24 (2009), 45–57.
23. Rizzi, E., Castro, M.M., Ceron, C.S., et al. Tempol inhibits TGF-beta and MMPs upregulation and prevents cardiac hypertensive changes. Int. J. Cardiol. 165 (2013), 165–173.
24. Lemarie, C.A., Tharaux, P.L., Lehoux, S., Extracellular matrix alterations in hypertensive vascular remodeling. J. Mol. Cell. Cardiol. 48 (2010), 433–439.
25. Serban, M.C., Sahebkar, A., Zanchetti, A., et al. Effects of quercetin on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc, 2016, 5.
26. Sanchez, M., Galisteo, M., Vera, R., et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. 24 (2006), 75–84.
27. Rice-Evans, C.A., Miller, N.J., Paganga, G., Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic. Biol. Med. 20 (1996), 933–956.
28. Montenegro, M.F., Neto-Neves, E.M., Dias-Junior, C.A., et al. Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension. Naunyn-Schmiedeberg's Arch. Pharmacol. 382 (2010), 293–301.
29. Wang, L., Cheng, X., Li, H., et al. Quercetin reduces oxidative stress and inhibits activation of cJun N terminal kinase/activator protein1 signaling in an experimental mouse model of abdominal aortic aneurysm. Mol. Med. Rep. 9 (2014), 435–442.
30. Bartekova, M., Simoncikova, P., Fogarassyova, M., et al. Quercetin improves postischemic recovery of heart function in doxorubicin-treated rats and prevents doxorubicin-induced matrix metalloproteinase-2 activation and apoptosis induction. Int. J. Mol. Sci. 16 (2015), 8168–8185.
31. Navarro, J.A., de Gouveia, L.A., Rocha-Penha, L., et al. Reduced levels of potential circulating biomarkers of cardiovascular diseases in apparently healthy vegetarian men. Clin. Chim. Acta 461 (2016), 110–113.
32. Dao, H.H., Lemay, J., de Champlain, J., et al. Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J. Hypertens. 19 (2001), 1965–1973.
33. Yogi, A., Callera, G.E., Mecawi, A.S., et al. Acute ethanol intake induces superoxide anion generation and mitogen-activated protein kinase phosphorylation in rat aorta: a role for angiotensin type 1 receptor. Toxicol. Appl. Pharmacol. 264 (2012), 470–478.
34. Barhoumi, T., Fraulob-Aquino, J.C., Mian, M.O.R., et al. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovasc. Res. 113 (2017), 1753–1762.
35. Edwards, R.L., Lyon, T., Litwin, S.E., et al. Quercetin reduces blood pressure in hypertensive subjects. J. Nutr. 137 (2007), 2405–2411.
36. Duarte, J., Perez-Palencia, R., Vargas, F., et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br. J. Pharmacol. 133 (2001), 117–124.
37. Lee, L.T., Huang, Y.T., Hwang, J.J., et al. Transinactivation of the epidermal growth factor receptor tyrosine kinase and focal adhesion kinase phosphorylation by dietary flavonoids: effect on invasive potential of human carcinoma cells. Biochem. Pharmacol. 67 (2004), 2103–2114.
38. Simplicio, J.A., do Vale, G.T., Gonzaga, N.A., et al. Reactive oxygen species derived from NAD(P)H oxidase play a role on ethanol-induced hypertension and endothelial dysfunction in rat resistance arteries. J. Physiol. Biochem. 73 (2017), 5–16.
39. Ceron, C.S., Rizzi, E., Guimaraes, D.A., et al. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-beta and MMPs, and decreases vascular remodeling in renovascular hypertension. Free Radic. Biol. Med. 65 (2013), 47–56.
40. Hertog, M.G., Feskens, E.J., Hollman, P.C., et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342 (1993), 1007–1011.
41. Newby, A.C., Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res. 69 (2006), 614–624.
42. Ruiz-Ortega, M., Rodriguez-Vita, J., Sanchez-Lopez, E., et al. TGF-beta signaling in vascular fibrosis. Cardiovasc. Res. 74 (2007), 196–206.
43. Ceron, C.S., Rizzi, E., Guimaraes, D.A., et al. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol. 31 (2012), 261–270.
44. Castro, M.M., Kandasamy, A.D., Youssef, N., et al. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol. Res. 64 (2011), 551–560.
45. Castro, M.M., Cena, J., Cho, W.J., et al. Matrix metalloproteinase-2 proteolysis of calponin-1 contributes to vascular hypocontractility in endotoxemic rats. Arterioscler. Thromb. Vasc. Biol. 32 (2012), 662–668.